← Back to Search

Serotonin-Norepinephrine Reuptake Inhibitor

Desvenlafaxine for Depression

Phase 4
Waitlist Available
Led By Corina Velehorschi, MD
Research Sponsored by Hotel-Dieu Grace Healthcare
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female subject between 60 and 80 years of age, at the time of consent.
Diagnosis of Major Depressive Disorder according to DSM-IV-TR at screening.
Screening 3 weeks
Treatment Varies
Follow Up 12-weeks
Awards & highlights

Study Summary

This trial will examine whether desvenlafaxine is an effective treatment for vascular depression, as well as assessing its safety. The primary efficacy measures will be depressive symptoms and cognition, both measured at baseline and 12 weeks. A sub-group of patients who have experienced a TIA will also be evaluated for efficacy.

Who is the study for?
This trial is for individuals aged 60-80 with Major Depressive Disorder and cognitive deficits, but not dementia. They must have white matter changes on MRI and be able to follow the study plan. Excluded are those non-compliant with treatments, with contraindications to desvenlafaxine, glaucoma, recent TIAs or strokes, current anticoagulant use, uncontrolled diabetes or hypertension.Check my eligibility
What is being tested?
The trial tests desvenlafaxine's effectiveness in treating vascular depression over a period of 12 weeks. It measures changes in depression severity using the Geriatric Depression Scale and cognitive function using the Montreal Cognitive Assessment.See study design
What are the potential side effects?
Desvenlafaxine may cause nausea, dizziness, insomnia, sweating, constipation and possible sexual side effects. It can also increase blood pressure and has a risk of causing serotonin syndrome when combined with other medications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am between 60 and 80 years old.
I have been diagnosed with Major Depressive Disorder.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12-weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12-weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Depressive Symptoms

Side effects data

From 2015 Phase 4 trial • 53 Patients • NCT01916824
Upper Respiratory Tract Infection
Study treatment Arm
Participants With Major Depressive Disorder
Healthy Controls

Trial Design

1Treatment groups
Experimental Treatment
Group I: Desvenlafaxine SuccinateExperimental Treatment1 Intervention
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Find a Location

Who is running the clinical trial?

Hotel-Dieu Grace HealthcareLead Sponsor
Corina Velehorschi, MDPrincipal InvestigatorHotel-Dieu Grace Healthcare

Media Library

Desvenlafaxine Succinate (Serotonin-Norepinephrine Reuptake Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT01974934 — Phase 4
Depression Research Study Groups: Desvenlafaxine Succinate
Depression Clinical Trial 2023: Desvenlafaxine Succinate Highlights & Side Effects. Trial Name: NCT01974934 — Phase 4
Desvenlafaxine Succinate (Serotonin-Norepinephrine Reuptake Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01974934 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who has the privilege of participating in this research trial?

"This research venture is admitting 30 geriatric patients suffering from vascular depression. Suitable candidates must meet the following eligibility criteria: subjects that are willing to comply with study visits and procedures, have given informed consent for participation in this trial, aged 60-80 years old at time of signing up, diagnosed with Major Depressive Disorder according DSM IV TR, evidence of DWMH on MRI scans, cognitive deficits not meeting dementia diagnosis (MMSE 21 or higher and CDR=0.5)."

Answered by AI

What is the current sample size of this research project?

"Unfortunately, active recruitment for this trial concluded on March 18th 2015. However, if you are searching for similar studies, there are currently 1287 trials actively enrolling patients with depression related to vascular issues and 2 distinct studies need participants taking Desvenlafaxine Succinate."

Answered by AI

Has the FDA sanctioned Desvenlafaxine Succinate for public use?

"Due to the fact that Desvenlafaxine Succinate is an approved treatment, our evaluation gave it a score of 3 on the risk scale."

Answered by AI

Are seniors accepted into this testing program?

"The requirements for this medical trial necessitate that applicants must be aged between 60 and 80 years old. There are 191 trials available to those under 18, while 964 can participate if they exceed the age of 65."

Answered by AI

What other explorations have been done with Desvenlafaxine Succinate?

"Presently, two clinical trials involving Desvenlafaxine Succinate are underway. One of the active studies is in its third phase and takes place primarily around Windsor, Ontario with seven additional locations offering this medication as part of a trial."

Answered by AI

Is this research pioneering in its methodology?

"Currently, two trials involving Desvenlafaxine Succinate are being conducted in four cities and two countries. This medication was first investigated by Jiangsu Hansoh Pharmaceutical Co., Ltd. in 2013; a Phase 2 & 3 drug approval program including 300 patients obtained the necessary data before concluding. Since its inception, 49 studies have concluded successfully."

Answered by AI

Are there any remaining vacancies in this medical trial?

"As evidenced on clinicaltrials.gov, this study is no longer actively seeking participants; its initial posting was December 1st 2013 and the last update occurred March 18th 2015. Despite not recruiting anymore, there are still 1289 other studies that currently require volunteers."

Answered by AI
~3 spots leftby Apr 2025